The small molecule inhibitor DFF332 elicited clinical activity and had a tolerable safety profile in patients with advanced clear cell renal cell carcinoma.
Many countries with national healthcare systems or payers such as insurance companies use cost-effectiveness analyses to decide whether to cover new medicines, balancing treatment costs with potential health benefits.
Survivorship starts the day someone receives a cancer diagnosis. It continues during and after treatment and on through the end of life. With early detection an
Southampton Unit Spearheads NHS Ground-breaking Cancer Vaccine Trial miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
31.05.2024 - The Southampton Clinical Trials Unit, based at the University of Southampton, has been chosen to run a new programme accelerating research into potentially ground-breaking cancer treatments. The Cancer Vaccine Launch Pad (CVLP) will improve patient access to clinical trials to test new investigational immunotherapies by speeding up the development of personalised cancer vaccines.